Spark Therapeutics Announces Updated Phase 1/2 Study Results Supporting the Durability of Investigational Gene Therapy SPK-8011 in Patients With Hemophilia A
12. Dezember 2022 12:00 ET
|
Spark Therapeutics, Inc.
Multi-year data, with up to five years of follow up, show sustained expression of FVIII in more than 90% of participants, in addition to improved annual bleeding and infusion ratesData shared during...